Pharmacologic Management of Primary Insomnia in Adults

First‑Line Pharmacologic Options

• Eszopiclone 2–3 mg – Provides the most robust evidence for both acute and long‑term treatment, with sustained efficacy beyond 4 weeks and moderate‑quality evidence, although it is associated with higher adverse‑event rates. 1, 2
• Zolpidem 10 mg – Effective for sleep onset and maintenance in acute treatment; long‑term data are limited and dropout rates due to side effects are higher. 1, 3
• Suvorexant 10–20 mg – Orexin‑receptor antagonist that improves sleep maintenance, offers better tolerability than traditional agents, and preserves natural sleep architecture. 1, 2

Agents Targeted to Specific Sleep Domains

Sleep‑Onset Only

• Zaleplon 10 mg – Well‑tolerated and limited to initiating sleep; efficacy data are scarce. 1, 3
• Ramelteon 8 mg – Melatonin‑receptor agonist for sleep onset but significantly less effective than benzodiazepine‑receptor agonists. 1, 2

Sleep‑Maintenance Only

• Doxepin 3–6 mg – Low‑dose tricyclic antidepressant that improves sleep maintenance with favorable tolerability; efficacy evidence is limited. 1, 2

Agents to Avoid (Negative Recommendations)

• Trazodone 50 mg – Harms outweigh benefits despite frequent off‑label use. 1, 4, 5
• Diphenhydramine 50 mg – Not recommended because anticholinergic effects are especially problematic in older adults. 1, 2, 5
• Melatonin 2 mg – Insufficient evidence of efficacy for primary insomnia. 1, 3
• Tiagabine, tryptophan, valerian – All carry negative recommendations due to lack of efficacy or unfavorable risk‑benefit profiles. 1, 2, 3

Safety Considerations

• Observational data link hypnotic use (including benzodiazepines) to increased risk of dementia, fractures, and major injuries. 6
• FDA reports identify cognitive and behavioral changes, such as impaired driving, associated with benzodiazepine hypnotics. 6
• Older adults should avoid benzodiazepines because of heightened fall and cognitive risks. 6

Dosing Adjustments

• Women and older adults – FDA advises dose reductions for most sleep‑aid pharmacotherapies due to altered metabolism and higher adverse‑event risk. 6
• Zolpidem – Requires a lower dose in women (5 mg) versus men (10 mg) because of slower clearance. 6

Polypharmacy and Treatment Duration

• Avoid combining hypnotics – No evidence supports combination therapy; concomitant use multiplies safety risks. 6
• Acute treatment – Efficacy data support a treatment window of 4–12 weeks for most agents. 6

Special Populations

• Patients with medical or psychiatric comorbidities – Evidence for most pharmacologic options is insufficient; priority should be given to treating the underlying condition, which may resolve insomnia. 6

Guideline Recommendations Against Amitriptyline for Insomnia

Guideline Stance

Regulatory Status

Safety Risks (Observational Evidence)

Evidence‑Based Dosing of Doxepin for Sleep‑Maintenance Insomnia

Recommended Dose and Indication

• The American Academy of Sleep Medicine (2017) recommends low‑dose doxepin only for sleep‑maintenance insomnia (difficulty staying asleep, frequent awakenings, early‑morning awakening); the recommendation is based exclusively on trials that used 3 mg or 6 mg capsules, not 10 mg capsules. 9, 10
• For patients with sleep‑onset insomnia, doxepin is ineffective; preferred alternatives are zaleplon 10 mg, ramelteon 8 mg, or zolpidem 10 mg (5 mg in women). 10

Efficacy Outcomes (Low‑Dose Doxepin)

• In randomized controlled trials, 3 mg–6 mg doxepin increased total sleep time by 26–32 minutes compared with placebo. (Evidence from RCTs; effect size small‑to‑moderate.) 9
• The same dose range reduced wake after sleep onset by 22–23 minutes versus placebo, indicating better sleep continuity. (RCT evidence.) 9
• Participants reported a small‑to‑moderate improvement in subjective sleep quality with 3 mg–6 mg doxepin. (RCT evidence.) 9
• No additional sleep benefit was demonstrated when the dose was increased to 10 mg; efficacy plateaued at the 3 mg–6 mg range. (RCT evidence.) 9, 10

Safety and Tolerability (Low‑Dose Doxepin)

• At 3 mg–6 mg, doxepin shows a favorable tolerability profile with minimal anticholinergic effects; common adverse events are mild next‑day drowsiness and dry mouth, which often resolve with continued use. (Clinical trial safety data.) 9
• Elderly patients are at higher risk for confusion, falls, and anticholinergic toxicity; starting at 3 mg and close monitoring are advised. (Guideline recommendation; safety data from trials.) 9
• Contraindications include glaucoma, urinary retention, and hypersensitivity to tricyclic antidepressants; these must be screened before prescribing. (Guideline safety considerations.) 9

Clinical Guidance and Common Pitfalls

• Initiate therapy at 3 mg nightly, taken about 30 minutes before bedtime, to selectively block histamine H1 receptors while minimizing tricyclic side effects. (Mechanistic rationale from trial data.) 9
• If response is insufficient after 1–2 weeks, titrate to 6 mg nightly; do not exceed 6 mg for insomnia because higher doses lack evidence of added benefit and increase adverse effects. (Step‑wise algorithm based on trial evidence.) 9, 10
• Avoid prescribing 10 mg for insomnia; the 10 mg capsule is intended for depression treatment and provides no extra sleep efficacy while increasing anticholinergic and sedative risks. (Evidence of lack of benefit and increased harm.) 9, 10
• Doxepin does not require tapering when discontinued, unlike benzodiazepines or Z‑drugs, simplifying deprescribing. (Guideline statement; no citation needed.)
• The drug’s niche is patients with sleep‑maintenance insomnia who cannot tolerate or prefer to avoid benzodiazepine‑receptor agonists; it offers an alternative with a distinct mechanism and safety profile. (Guideline positioning.) 9

*All facts are derived from peer‑reviewed evidence cited above and reflect the strength of evidence as reported in the 2017 American Academy of Sleep Medicine guideline (primarily randomized controlled trials).

Guideline Recommendations for Initiating Dual Orexin Receptor Antagonists in Chronic Insomnia

1. Indications and Timing of Initiation

• The American Academy of Sleep Medicine (AASM) recommends that dual orexin receptor antagonists (DORAs) be started immediately after documented failure of cognitive‑behavioral therapy for insomnia (CBT‑I) or when CBT‑I is unavailable, positioning them as first‑line pharmacologic options with a superior safety profile compared with traditional GABAergic hypnotics. 11

2. Agent Selection Based on Sleep Complaint

• According to the AASM, suvorexant is the preferred DORA for sleep‑maintenance insomnia when non‑pharmacologic measures are insufficient, serving as an evidence‑based alternative to benzodiazepine‑receptor agonists. 11
• The same AASM source notes that suvorexant 10–20 mg (15 mg in adults ≥ 65 years) is effective for sleep‑maintenance insomnia but produces smaller effect sizes for maintaining sleep compared with lemborexant and daridorexant. 11

3. Initial Dosing and Titration (Suvorexant)

• Initial dose: 10 mg taken within 30 minutes of bedtime, ensuring at least 7 hours of sleep opportunity before planned awakening. (Adult population with chronic insomnia.) 11
• Titration: If the 10 mg dose is insufficient after 1–2 weeks, increase to 20 mg (or 15 mg in adults ≥ 65 years). 11

4. Duration of Therapy

• The AASM states that short‑term (acute) treatment of 4–12 weeks with any DORA is supported by robust efficacy data, confirming their suitability for acute insomnia management. 11

5. Diagnostic Confirmation Prior to Therapy

• Before prescribing a DORA, clinicians should confirm a diagnosis of chronic insomnia and document failure of non‑pharmacologic interventions such as CBT‑I, as recommended by the AASM. 11

Non‑Controlled Pharmacologic Management of Adult Insomnia (American Academy of Sleep Medicine Guidelines)

First‑Line Options – Sleep‑Onset Insomnia

• The American Academy of Sleep Medicine (AASM) recommends ramelteon 8 mg taken ≈30 minutes before bedtime as the preferred non‑controlled agent for sleep‑onset difficulty, emphasizing its melatonin‑receptor agonism, minimal abuse potential, and favorable safety profile. 12
• Evidence from the AASM shows that ramelteon reduces sleep latency, but its effect size is significantly smaller than that of benzodiazepine‑receptor agonists. 13

First‑Line Options – Sleep‑Maintenance Insomnia

• The AASM states that low‑dose doxepin (3–6 mg) is the preferred non‑controlled medication for sleep‑maintenance problems, representing the strongest evidence among non‑controlled agents. 12
• The AASM endorses suvorexant 10–20 mg (orexin‑receptor antagonist) as an alternative for sleep‑maintenance insomnia, noting superior tolerability versus older hypnotics and lower abuse potential than GABAergic agents. 12

Lack of Dual‑Action Evidence

• The AASM concludes that no non‑controlled medication has strong evidence for simultaneously treating both sleep‑onset and sleep‑maintenance insomnia. 13

Medications with Negative Recommendations

• The AASM issues a negative recommendation against trazodone for any type of insomnia, stating that harms outweigh any potential benefits. 12
• The AASM advises against diphenhydramine for insomnia because of anticholinergic adverse effects—particularly in older adults—and provides a formal negative recommendation for both sleep‑onset and sleep‑maintenance use. 12
• The AASM does not recommend over‑the‑counter melatonin for adult insomnia, citing insufficient evidence of efficacy for either sleep‑onset or sleep‑maintenance outcomes. 12
• The AASM issues negative recommendations for tiagabine, tryptophan, and valerian due to lack of efficacy or unfavorable risk‑benefit profiles. 12

Patient‑Specific Considerations

• The AASM advises that patients with a history of substance‑use disorder, age ≥ 65 years, cognitive‑impairment concerns, or anticholinergic sensitivity should preferentially receive ramelteon, low‑dose doxepin, or suvorexant, and avoid controlled substances. 12